The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here.
Bakky, did you attend the DYPD event? Anything interesting in it?
Loads of little 5k sells - wonder what that’s all about?! Someone trying to tease the bid down?
Sentiment? Nah, let's just wallow in self pity, much more entertaining!
I just wondered why you were very surprised given you haven't been happy with company newsflow / comms? We know the core product revenues were impacted by Covid-19 in H1 so the results won't be great and based on that I didn't think they'd be in a mad rush to announce them!
I suspect they're wanting to see the order flow for H2 to hopefully come out with an upbeat statement and revenue confirmation for H2 / FY. It's all about the guidance and re-iteration of the FY target IMO.
Why are you very surprised?
Looks interesting here - strong revenues, profitable, cash in the bank and a tiny MCAP! Due a re-rate?!
The term used wrt to core business was “resilient”... they didn’t say core NIPT business was growing exactly as planned pre-covid ...
ADJECTIVE [usually verb-link ADJECTIVE]
People and things that are resilient are able to recover easily and quickly from unpleasant or damaging events.
Oi, you two BOD members ... When’s the RNS coming out about my promotion to BB Sentiment Analysis director?!
Ps. You still owe me £2.70 for my October posts!
Would 28p get the deal done? I guess it depends if the SP moves significantly before an offer is made!
It seems like a more hands on CSO, with Bill moving to more of a business role ...
Shall we all get depressed about it?
Although pretty much irrelevant given we're processing at our current capacity and can probably fill any incremental capacity with private high margin testing, is there anything that stops us processing other tests as a lab service, for example the PremierDesign test?
Why can't the active swab just be put in the deactivating liquid before processing? It is then deactivated and compatible?
So, if Lyn had been more specific about the impact to NIPT business say in the June timeframe, what do you think would’ve happened to the share price?
It would almost certainly have dropped, right?
Sentiment would be lower, right?
Then what would’ve happened when he raised money later in the summer?
Yes, you’ve guessed it ..., it would’ve almost certainly been at a lower price and therefore caused more dilution, right?
Would all the BB armchair CEO’s who think they can do a better job be happier with that? A lower SP and more dilution - just to feel informed? Needing to hear before the H1 trading update that one region for one part of the business had a blip due to the global pandemic?
We have around £12m in the bank, new products and services ramping up and despite the blip in H1, confirmed commitment to the £24.8/£25m revenue targets for FY.
IMO, he has acted in the best interests of shareholders, resiliently :=)
If he doesn’t make his £24.8m by year end, I’ll have custard with my humble pie, thanks!
From a glass half full perspective, the IONA NX sales should be coming online, and DYPD (the weed) May also come to the rescue.
Thank god (or is that the Bod) that we are now a broader company than just NIPT on the TF platform eh?! We also have nearly £12m in the bank , and at worst case have £500k a month income from testing for another 6 months.
If we make £25m revenue this year, that’s about 50% growth in a pandemic ...
Is it really that depressing?!
They said resilient ..
adjective
1. (of a person or animal) able to withstand or recover quickly from difficult conditions.
Well, ultimately you have to decide whether you believe this or not ...
“Our full year outlook remains in line with management expectations and we look forward to updating investors again when we publish our half-year results in December.”
.. and if you don't, perhaps identify other investments with better prospects? Writing two page essays here will make no difference to anything except your blood pressure!
In N+1 SInger's note today, they still have FY revenue at £24.8m. From this, we can assume that today's update was not a surprise to them and that they were aware of some tricky market conditions for NIPT in some regions.
Hopefully they are equally aware of the strong start and expected growth for H2 since they have not revised their estimates.
IMO, we are already feeling the benefit of the wider product suite, with DYPD generating strong momentum. We have yet to realise anything from IONA NX too, which should help us make those H2 numbers!
N+1 Singer are sticking with their £24.8m FY estimate, the TU remains in line with their expectations...
.. "and would like to point out the following as, inter alia, being supportive to the FY estimates, i) the acqusition of Coastal Genomics and x5 Genomics towards the end of the period; ii) growth in DYPD; iii) recovery in momentum in NIPT post the launch of IONA Nx in September opening up new customers and markets, and iv) the launch and expansion of the group's Covid-19 services and products."
"Net cash at end of period was £11.9m"
I was going to say only 1 MM left on the ask but quicker than I could type, they moved to 20p .. We now have 3MM's on the bid at 19p (90k) and two on the ask at 20p (60k) .. latest live trade, a buy of 79694 buy at 19.98p
If we get any cheaper, NCYT might just buy us with their petty change to broaden their testing range beyond Covid testing!